Provided herein are bioactivated polymer/extracellular matrix (ECM) composites and methods of preparation and use thereof. In particular, heparinized cysteine-polymer/ECM composites, and methods of preparation and use thereof, are provided. In some embodiments, provided herein are compositions comprising a composite of: (a) extracellular matrix (ECM), and (b) a polyester covalently linked to a bioactive agent. In some embodiments, the composite is a homogeneous composite. In some embodiments, the ECM is decellularized ECM. In some embodiments, the ECM is not substantially crosslinked.

The present invention involves implants suitable for surgical implantation into subjects. In some embodiments the implants comprise a biocompatible scaffold material and blood vessels containing engineered endothelial cells—such as E4ORF1+ engineered endothelial cells or engineered endothelial cells that express certain marker molecules. The present invention provides implants, methods for preparing such implants, and methods of treatment utilizing such implants.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Described embodiments are directed toward centrally-opening leaflet prosthetic valve devices having synthetic leaflets that are configured to promote and encourage tissue ingrowth thereon and/or therein. The leaflets are coupled to a leaflet frame to form a prosthetic valve suitable for use in biological anatomy.

An intravascular cell therapy device comprises a scaffold (2, 12) that is radially adjustable between a contracted orientation suitable for transluminal delivery to a vascular locus and an expanded orientation, and a biodegradable matrix provided on at least a portion of the scaffold that is suitable for seeding with cells and degrades in a vascular environment. The scaffold is configured to have a distal piercing tip (5) when in a deployed orientation. The scaffold comprises a plurality of sidewall panels (3, 13, 14) arranged around a longitudinal axis of the scaffold, and adjustable couplings (4) between the panels configured for adjustment between an expanded configuration and a contracted orientation, and in which each sidewall panel comprises a matrix suitable for seeding with cells.

The invention relates to a method for predicting or diagnosing a risk of bioprosthetic valve degeneration. Further, the invention relates to a medical device, in particular a bioprosthetic valve coated with EPCR less prone to degeneration and/or calcification once implanted.

The invention relates to generally to a vascular access graft that includes a magnetic element disposed about a flow tube for guiding a blood flow between an arterial end adapted for arterial anastomosis to a portion of an artery, and a venous end adapted for venous anastomosis to a portion of a vein. The magnetic element may include a plurality of magnets disposed about the flow tube so that a magnetic field may be applied to blood flowing therein; the magnetic element may alternatively include a circuitry configured to generate a magnetic field applied to the flow tube.

Bioabsorbable medical devices such as vascular closures, mitral chorea replacements, and mitral leaflet extensions are provided.

Provided herein are biodegradable copolymers, methods of lactone polymerization, nanofibrous scaffolds, and methods of regenerating tissue.

Poly(glycerol sebacate) (PGS) polymers, which may be referred to as a functionalized poly(glycerol sebacate) polymers. The PGS polymers include pendant aliphatic carboxyl ate groups and/or pendant aryl carboxyl ate groups covalently bound to the glycerol group of the glycerol sebacate backbone of the polymer. Polymeric materials including a plurality of glycerol sebacate groups, where at least a portion of the individual glycerol sebacate groups have a pendant aliphatic carboxylate group and/or pendant aryl carboxyl ate group covalently bound to the glycerol group of the glycerol sebacate group. The PGS polymers or polymeric materials may be crosslinked PGS polymers or polymeric materials. The PGS polymers and polymeric materials may be made by post-polymerization functionalization. The PGS polymers and polymeric materials may be in fiber form. A material, which may be a fabric, may include a fiber or plurality of fibers. A material may be used to form a tissue graft.